| P2093 | author name string | Yvonne S Lin | |
| | Jialin Mao | |
| | Manoli Vourvahis | |
| | Robert van Horn | |
| | James McLeod | |
| | Iain Martin | |
| | Gail Nolan | |
| P2860 | cites work | Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model | Q41556479 |
| | Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. | Q42144199 |
| | Esterification of oxysterols by human plasma lecithin-cholesterol acyltransferase | Q42279088 |
| | Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? | Q43144692 |
| | 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin | Q43146767 |
| | Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients | Q43522537 |
| | Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin | Q43633681 |
| | Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment | Q43934377 |
| | 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians | Q43944775 |
| | CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population | Q43946631 |
| | Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients | Q44132038 |
| | In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam | Q45095095 |
| | Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin | Q45116652 |
| | Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? | Q46003084 |
| | There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found | Q46430562 |
| | Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol | Q46466256 |
| | Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. | Q46495913 |
| | CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition | Q46580820 |
| | CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels | Q46610452 |
| | Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitro | Q48023510 |
| | Bile acid malabsorption deactivates pregnane X receptor in patients with Crohn's disease. | Q51076088 |
| | Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction. | Q53804885 |
| | Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease. | Q54586923 |
| | Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis | Q56829837 |
| | Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin | Q57825152 |
| | Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians | Q58003103 |
| | Do oxysterols control cholesterol homeostasis? | Q24553299 |
| | Genetic contribution to variable human CYP3A-mediated metabolism | Q28212042 |
| | Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis | Q28367522 |
| | Circadian variation of the urinary 6beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity | Q33421769 |
| | Oxysterols and their cellular effectors | Q33649595 |
| | Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration | Q33692808 |
| | Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin | Q33870649 |
| | Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions | Q34012134 |
| | Hepatic cytochrome P450 regulation in disease states | Q34317438 |
| | Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects | Q34570949 |
| | Regulation of drug-metabolizing enzymes and transporters in inflammation | Q36364663 |
| | The human intestinal cytochrome P450 "pie". | Q36420382 |
| | Cholesterol sensing, trafficking, and esterification. | Q36497100 |
| | Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy | Q36729155 |
| | 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? | Q36802040 |
| | A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction | Q36948140 |
| | Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation | Q37076544 |
| | Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers | Q37325725 |
| | Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport | Q38153196 |
| | Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach. | Q38413336 |
| | CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease | Q38847546 |
| | Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity | Q38878983 |
| | Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis | Q39732430 |
| | Metabolism of 4 beta -hydroxycholesterol in humans. | Q40723392 |
| | Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. | Q40784945 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 18-34 | |
| P577 | publication date | 2016-10-10 | |
| P1433 | published in | Drug Metabolism Reviews | Q5308857 |
| P1476 | title | Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. | |
| P478 | volume | 49 | |